** Eye-drug maker Harrow's HROW shares rise 2.09% to $31.32
** Brokerage H.C. Wainwright starts coverage on HROW with "buy" rating; sets PT at $57
** Brokerage sees rapid growth driven by co's branded products for eye diseases
** Expects HROW to continue to make meaningful and sensible buys
** Says its eye drop Vevye compares well to other dry eye treatments
** Says that other eye products that are used during surgical procedures such as Iheezo and Triesence also serve as growth drivers
** The PT is a 84.5% upside to the stock's last close
** Stock rose ~232% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.